VERICEL CORPORATION
Last · NASDAQ$40.25-0.05 (-0.12%)close · yahoo · 16h ago
Vol 384.5K ≈ 15.48M
MA10MA20MA50
Market cap$2.06B51.2M sh
P/E · TTM85.6fwd 47.6 · eps 0.47
Beta1.02vs S&P 500
Div yield0.00%annual · TTM
52w range
$28.95$49.32
Volume384.5Ksession
Issuer
Legal nameVERICEL CORPORATION
HQUnited States (US)
ListingUS VCEL
ISINUS92346J1088
SectorHealthcare
IndustryDrugs (Biotechnology)
SIC2836
CurrencyUSD
Entity registrysec:0000887359
CIK0000887359
Websitewww.vcel.com
Employees398
AddressVericel Corp. 64 Sidney Street 02139-4170, Cambridge +617 588 5555
| Revenue | $306.3M |
|---|---|
| Operating income | $-7.6M |
| Net income | $-4.1M |
| Free cash flow | $29.4M |
| Operating margin | -2.5% |
| Net margin | -1.3% |
| Return on equity | -1.1% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
10-K · 2026-02-26
From latest 10-K · 2026-02-26
- Accumulated Deficit High
Red flags
- Accumulated Deficit High — Accumulated deficit / equity 106%
Upcoming earnings
THU.5NOV
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$0.06
Est. revenue
78.0M
Press & signals
- GlobeNewswire
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program